- preweaning lethality, complete penetrance / IMPC
- embryonic growth retardation / IMPC
- edema / IMPC
- abnormal embryo size / IMPC
- increased circulating alanine transaminase level / IMPC
- anophthalmia / IMPC
- impaired pupillary reflex / IMPC
- abnormal limb morphology / IMPC
- decreased mean corpuscular hemoglobin / IMPC
B6;129P2-Elavl1tm1Dkon/Flmg
| Status | Available to order |
| EMMA ID | EM:04960 |
| Citation information | RRID:IMSR_EM:04960 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
| International strain name | B6;129P2-Elavl1tm1Dkon/Flmg |
| Alternative name | Elavl1 fl/fl |
| Strain type | Targeted Mutant Strains : Conditional mutation |
| Allele/Transgene symbol | Elavl1tm1Dkon |
| Gene/Transgene symbol | Elavl1 |
Information from provider
| Provider | Dimitris KONTOYIANNIS |
| Provider affiliation | Immunology, B.S.R.C. Alexander Fleming |
| Genetic information | A targeting vector was designed to flank a 0.77-kb XbaI/EcoRI fragment containing the second exon of the Elavl1 gene with loxP sequences and placed adjacent to a loxP-flanked PMC-neo-pA neomycin resistance gene. 5' and 3' homology regions of 4.4 kb (EcoRI/XbaI) and 5.7 kb (EcoRI), respectively, were inserted on either side of the modified exon 2 sequences. Finally, the complete modified locus was subcloned at the 5' end of a herpes simplex virus thymidine kinase susceptibility gene for the negative selection of random integrants. Targeting procedures in 129/Ola embryonic stem cells and subsequent injections in C57BL/6 blastocysts for chimera production and germ-line transmission from three independent clones were performed using standard procedures. |
| Phenotypic information | This is a strain that can be used with tissue specific Cre expressing strains to induce Cre-mediated Elavl1 (HuR) ablation. |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | B.S.R.C. Alexander Fleming, Vari, Greece |
| Animals used for archiving | homozygous C57BL/6 males, wild-type C57BL/6 females |
| Stage of embryos | 8-cell |
Disease and phenotype information
IMPC phenotypes (gene matching)
MGI phenotypes (gene matching)
- decreased bone marrow cell number / MGI
- spleen hypoplasia / MGI
- decreased trophoblast giant cell number / MGI
- placental labyrinth hypoplasia / MGI
- pale yolk sac / MGI
- thymus hypoplasia / MGI
- increased cellular sensitivity to gamma-irradiation / MGI
- embryonic growth retardation / MGI
- abnormal maternal decidual layer morphology / MGI
- small placenta / MGI
- abnormal chorionic plate morphology / MGI
- abnormal placental labyrinth vasculature morphology / MGI
- abnormal spongiotrophoblast cell morphology / MGI
- lethality throughout fetal growth and development, complete penetrance / MGI
- preweaning lethality, complete penetrance / MGI
- embryonic lethality during organogenesis, incomplete penetrance / MGI
- decreased spongiotrophoblast size / MGI
Literature references
- Control of thymic T cell maturation, deletion and egress by the RNA-binding protein HuR.;Papadaki Olympia, Milatos Stavros, Grammenoudi Sofia, Mukherjee Neelanjan, Keene Jack D, Kontoyiannis Dimitris L, ;2009;Journal of immunology (Baltimore, Md. : 1950);182;6779-88; 19454673
- Divergent Innate and Epithelial Functions of the RNA-Binding Protein HuR in Intestinal Inflammation.;Christodoulou-Vafeiadou Eleni, Ioakeimidis Fotis, Andreadou Margarita, Giagkas Giorgos, Stamatakis George, Reczko Martin, Samiotaki Martina, Papanastasiou Anastasios D, Karakasiliotis Ioannis, Kontoyiannis Dimitris L, ;2018;Frontiers in immunology;9;2732; 30532756
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).
